查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589848

法布瑞氏症治療市場：依治療類型、藥物、給藥途徑- 全球預測 2025-2030

Fabry Disease Treatment Market by Treatment Type (Chaperone Treatment, Enzyme Replacement Therapy, Organ-Specific Treatment), Drugs (Agalsidase Beta, Migalastat, Pipeline Drugs), Route of Administration - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

法布瑞氏症治療市場2023年估值為25億美元，預計2024年將達27.1億美元，複合年成長率為8.47%，預計2030年將達44.1億美元。

法布瑞氏症治療市場範圍包括旨在控制這種罕見遺傳性溶小體貯積症症狀和減緩疾病進展的治療解決方案。這包括酵素替代療法、Chaperone療法、基材減少療法和潛在的基因療法，市場擴展到特種藥物和生物技術創新。法布瑞氏症有效治療的需求源自於需要緩解疼痛、腎衰竭和心臟併發症等嚴重症狀，並顯著改善患者的生活品質。這些治療方法適用於醫院、專科治療中心和居家醫療機構，最終用途包括患有這種疾病的兒童和成人患者。市場洞察表明，關鍵因素包括由於診斷改進而導致患病率上升、促進早期療育的患者意識提高以及大型生物製藥公司為擴大治療選擇而對研發進行的大量投資，這已成為主要的成長要素。此外，孤兒藥的監管激勵措施正在促進該市場的創新。

主要市場統計
基準年[2023] 25億美元
預測年份 [2024] 27.1億美元
預測年份 [2030] 44.1億美元
複合年成長率（%） 8.47%

潛在的商機在於基因治療和個人化醫療的進步，提供變革性的治療方法。及時的建議包括利用策略合作夥伴關係並專注於現實世界的資料收集，以提高治療效果和患者結果。然而，高昂的治療成本、有限的患者群體和嚴格的監管要求等挑戰正在限制市場的成長。此外，罕見疾病治療的核准和報銷政策的不可預測性使市場動態更加複雜。創新和研究應著重於最佳化治療方法和開發新型藥物傳輸技術，例如奈米顆粒和基於 CRISPR 的解決方案，以提高生物有效性並減少副作用。法布瑞氏症治療市場的特點是其特殊性，需要利基行銷策略並培養持續臨床開發的環境，以利用科學突破。

市場動態：快速發展的法布瑞氏症治療市場的關鍵市場洞察

供需的動態交互作用正在改變法布瑞氏症治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 對傳訊RNA治療方法法布瑞氏症的需求不斷成長
    • 臨床試驗數量增加
    • 提高遺傳疾病的盛行率和認知
  • 市場限制因素
    • 對法布瑞氏症治療進展缺乏認知
  • 市場機會
    • 法布瑞氏症治療的持續研究與開發
    • 新興國家醫療保健支出增加和基礎設施改善
  • 市場挑戰
    • 某些國家對引進新技術的限制

波特五力：開拓法布瑞氏症治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解法布瑞氏症治療市場的外在影響

外部宏觀環境因素在塑造法布瑞氏症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解法布瑞氏症治療市場的競爭狀況

對法布瑞氏症治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣法布瑞氏症治療市場供應商的績效評估

FPNV定位矩陣是評估法布瑞氏症治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了法布瑞氏症治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，法布瑞氏症治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 作為法布瑞氏症的治療方法，對傳訊RNA的需求增加
      • 臨床試驗增加
      • 遺傳疾病的發生率和認知不斷提高
    • 抑制因素
      • 對法布瑞氏症治療進展缺乏認知
    • 機會
      • 法布瑞氏症治療的持續研究與開發
      • 新興國家醫療保健成本上升和基礎設施改善
    • 任務
      • 某些國家對引進新技術的限制
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療類型分類的法布瑞氏症治療市場

  • Chaperone治療
  • 酵素替代療法
  • 器官特異性治療
  • 基材減少療法

第7章 法布瑞氏症藥物治療市場

  • 阿加糖酶BETA
  • 米加司他
  • 管道藥品

第8章法布瑞氏症治療市場：依給藥途徑

  • 靜脈
  • 口服

第9章 美洲法布瑞氏症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區法布瑞氏症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲法布瑞氏症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amicus Therapeutics Inc.
  • Avrobio Inc.
  • BioMarin
  • Biosidus SA
  • Digestive Care, Inc.
  • GlaxoSmithKline PLC
  • Idorsia Pharmaceuticals Ltd.
  • ISU Abxis Co Ltd.
  • JCR Pharmaceuticals Co Ltd.
  • Leadiant Biosciences, Inc.
  • Nestle Health Science
  • Pfizer Inc.
  • Protalix Biotherapeutics Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4348D129FB16

The Fabry Disease Treatment Market was valued at USD 2.50 billion in 2023, expected to reach USD 2.71 billion in 2024, and is projected to grow at a CAGR of 8.47%, to USD 4.41 billion by 2030.

The scope of the Fabry disease treatment market encompasses therapeutic solutions aimed at managing symptoms and slowing disease progression for this rare genetic lysosomal storage disorder. This includes enzyme replacement therapies, chaperone therapies, substrate reduction therapies, and potentially gene therapies, with the market extending to specialty pharmaceuticals and biotechnological innovations. The necessity for effective Fabry disease treatments stems from the need to alleviate severe symptoms such as pain, renal failure, and cardiac complications, significantly improving patients' quality of life. These treatments find application across hospitals, specialized treatment centers, and homecare settings, with end-use scope including both pediatric and adult patient populations affected by the disease. Market insights reveal key growth factors including increasing prevalence rates owing to improved diagnostics, heightened patient awareness facilitating early intervention, and substantial R&D investments from major biopharmaceutical companies aiming to expand therapeutic options. Moreover, regulatory incentives for orphan drugs foster innovation within this market.

KEY MARKET STATISTICS
Base Year [2023] USD 2.50 billion
Estimated Year [2024] USD 2.71 billion
Forecast Year [2030] USD 4.41 billion
CAGR (%) 8.47%

Potential opportunities lie in the advancement of gene therapy and personalized medicine, offering transformative treatment modalities. Timely recommendations include leveraging strategic collaborations and focusing on real-world data collection to enhance therapeutic efficacy and patient outcomes. However, challenges such as high treatment costs, limited patient populations, and rigorous regulatory requirements pose constraints on market growth. Furthermore, the unpredictable nature of rare disease treatment approvals and reimbursement policies further complicate market dynamics. Innovation and research should pivot towards optimizing treatment regimens and developing novel drug delivery technologies, such as nanoparticle and CRISPR-based solutions, to improve bioavailability and reduce adverse effects. The Fabry disease treatment market is characterized by its specialized nature, necessitating niche marketing strategies and fostering an environment of continuous clinical development to capitalize on scientific breakthroughs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fabry Disease Treatment Market

The Fabry Disease Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for messenger RNA as a treatment modality for Fabry disease
    • Increasing number of clinical trials
    • Growing incidences of genetic disorders and increasing awareness
  • Market Restraints
    • Lack of awareness about advancements with respect to treatments for Fabry disease
  • Market Opportunities
    • Ongoing research and development for the treatment of Fabry disease
    • Increasing healthcare expenditure and improving infrastructure in emerging economies
  • Market Challenges
    • Limitations in adopting new technologies in certain countries

Porter's Five Forces: A Strategic Tool for Navigating the Fabry Disease Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fabry Disease Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fabry Disease Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fabry Disease Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fabry Disease Treatment Market

A detailed market share analysis in the Fabry Disease Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fabry Disease Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fabry Disease Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fabry Disease Treatment Market

A strategic analysis of the Fabry Disease Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fabry Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Amicus Therapeutics Inc., Avrobio Inc., BioMarin, Biosidus S.A., Digestive Care, Inc., GlaxoSmithKline PLC, Idorsia Pharmaceuticals Ltd., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Leadiant Biosciences, Inc., Nestle Health Science, Pfizer Inc., Protalix Biotherapeutics Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Fabry Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Chaperone Treatment, Enzyme Replacement Therapy, Organ-Specific Treatment, and Substrate Reduction Therapy.
  • Based on Drugs, market is studied across Agalsidase Beta, Migalastat, and Pipeline Drugs.
  • Based on Route of Administration, market is studied across Intravenous and Oral.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for messenger RNA as a treatment modality for Fabry disease
      • 5.1.1.2. Increasing number of clinical trials
      • 5.1.1.3. Growing incidences of genetic disorders and increasing awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness about advancements with respect to treatments for Fabry disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for the treatment of Fabry disease
      • 5.1.3.2. Increasing healthcare expenditure and improving infrastructure in emerging economies
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations in adopting new technologies in certain countries
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Fabry Disease Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Chaperone Treatment
  • 6.3. Enzyme Replacement Therapy
  • 6.4. Organ-Specific Treatment
  • 6.5. Substrate Reduction Therapy

7. Fabry Disease Treatment Market, by Drugs

  • 7.1. Introduction
  • 7.2. Agalsidase Beta
  • 7.3. Migalastat
  • 7.4. Pipeline Drugs

8. Fabry Disease Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral

9. Americas Fabry Disease Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Fabry Disease Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Fabry Disease Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amicus Therapeutics Inc.
  • 2. Avrobio Inc.
  • 3. BioMarin
  • 4. Biosidus S.A.
  • 5. Digestive Care, Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Idorsia Pharmaceuticals Ltd.
  • 8. ISU Abxis Co Ltd.
  • 9. JCR Pharmaceuticals Co Ltd.
  • 10. Leadiant Biosciences, Inc.
  • 11. Nestle Health Science
  • 12. Pfizer Inc.
  • 13. Protalix Biotherapeutics Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. FABRY DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. FABRY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FABRY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FABRY DISEASE TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY CHAPERONE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORGAN-SPECIFIC TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY AGALSIDASE BETA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY MIGALASTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY PIPELINE DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FABRY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023